Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA032119 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA032119, RRID:AB_10602806
- Product name
- Anti-FAM161A
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human FAM161A, Gene description: family with sequence similarity 161, member A, Alternative Gene Names: FLJ13305, RP28, Validated applications: IHC, Uniprot ID: Q3B820, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Fine-tuning FAM161A gene augmentation therapy to restore retinal function
Gene augmentation therapy attenuates retinal degeneration in a knockout mouse model of Fam161a retinitis pigmentosa
Retinal Structure and Function in a Knock-in Mouse Model for the FAM161A-p.Arg523∗ Human Nonsense Pathogenic Variant
Abnormal centriolar biomarker ratios correlate with unexplained bull artificial insemination subfertility: a pilot study.
Translational Read-Through Drugs (TRIDs) Are Able to Restore Protein Expression and Ciliogenesis in Fibroblasts of Patients with Retinitis Pigmentosa Caused by a Premature Termination Codon in FAM161A
A new mouse model for retinal degeneration due to Fam161a deficiency
Arsenijevic Y, Chang N, Mercey O, El Fersioui Y, Koskiniemi-Kuendig H, Joubert C, Bemelmans A, Rivolta C, Banin E, Sharon D, Guichard P, Hamel V, Kostic C
EMBO Molecular Medicine 2024;16(4):805-822
EMBO Molecular Medicine 2024;16(4):805-822
Gene augmentation therapy attenuates retinal degeneration in a knockout mouse model of Fam161a retinitis pigmentosa
Matsevich C, Gopalakrishnan P, Chang N, Obolensky A, Beryozkin A, Salameh M, Kostic C, Sharon D, Arsenijevic Y, Banin E
Molecular Therapy 2023;31(10):2948-2961
Molecular Therapy 2023;31(10):2948-2961
Retinal Structure and Function in a Knock-in Mouse Model for the FAM161A-p.Arg523∗ Human Nonsense Pathogenic Variant
Matsevich C, Gopalakrishnan P, Obolensky A, Banin E, Sharon D, Beryozkin A
Ophthalmology Science 2023;3(1):100229
Ophthalmology Science 2023;3(1):100229
Abnormal centriolar biomarker ratios correlate with unexplained bull artificial insemination subfertility: a pilot study.
Turner KA, Achinger L, Kong D, Kluczynski DF, Fishman EL, Phillips A, Saltzman B, Loncarek J, Harstine BR, Avidor-Reiss T
Scientific reports 2023 Oct 26;13(1):18338
Scientific reports 2023 Oct 26;13(1):18338
Translational Read-Through Drugs (TRIDs) Are Able to Restore Protein Expression and Ciliogenesis in Fibroblasts of Patients with Retinitis Pigmentosa Caused by a Premature Termination Codon in FAM161A
Beryozkin A, Samanta A, Gopalakrishnan P, Khateb S, Banin E, Sharon D, Nagel-Wolfrum K
International Journal of Molecular Sciences 2022;23(7):3541
International Journal of Molecular Sciences 2022;23(7):3541
A new mouse model for retinal degeneration due to Fam161a deficiency
Beryozkin A, Matsevich C, Obolensky A, Kostic C, Arsenijevic Y, Wolfrum U, Banin E, Sharon D
Scientific Reports 2021;11(1)
Scientific Reports 2021;11(1)
No comments: Submit comment
No validations: Submit validation data